$OMH

This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Angi (NASDAQ:ANGI), Ohmyhome (NASDAQ:OMH)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Original reporting
Benzinga · Avi Kapoor
Published Jun 16, 2025, 1:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2025, 2:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Angi (NASDAQ:ANGI), Ohmyhome (NASDAQ:OMH) — source image
Decision brief

The 30-second read

$OMHNeutralMed
01

Why it matters

The upgrade of ANGIV suggests positive momentum, while downgrades elsewhere indicate caution. Overall market impact is moderate.

02

Market read

The news primarily affects biotech stocks, especially ANGIV and SRPT, with limited impact on other sectors.

03

What to watch

Potential upcoming clinical trial results or regulatory decisions that could significantly impact these stocks.

Timing: Short-term (next 1-2 weeks)

Background

Recent analyst downgrades and upgrades reflect evolving market perceptions of these companies, especially in the biotech sector.

Company-level read

Ticker impact

$OMHNeutralMedium confidence
Context

Low relevance due to neutral sentiment and small impact from analyst downgrade.

Expected impact

No significant price movement expected in the short term.

Evidence & confidence

The neutral sentiment and low relevance score suggest limited influence on OMH's stock price.

$SRPTBullishMedium confidence
Context

Moderate relevance; somewhat-bullish sentiment indicates potential upward movement.

Expected impact

Possible slight upward movement; monitor technical levels.

Evidence & confidence

The mixed sentiment suggests cautious optimism, but technical analysis should guide timing.

Market effects

Potential positive sentiment in the biotech and healthcare sectors due to ANGIV's upgrade.

Limited; primarily US-based stocks affected.

Low; news pertains mainly to US equities and sector-specific developments.

Counterpoint

Some analysts may view the downgrade of Sarepta as a sign of underlying issues, cautioning against overconfidence in the bullish sentiment.

Key entities

  • Sarepta Therapeutics

    Biotech firm specializing in neuromuscular disease treatments.

  • ANGIV

    NASDAQ listed biotech stock with recent positive analyst sentiment.

  • OMH

    Ohmyhome, a real estate platform, with neutral analyst outlook.

  • PRO

    ProShares, a financial services company, with neutral outlook.

  • PKG

    Packaging Corporation of America, with neutral sentiment.

Related articles

$SRPTMedAI 8/10

Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline

Sarepta Therapeutics reported Q2 2026 net product revenue of $328.7M, with GAAP operating income of $13.3M and non-GAAP operating income of $86.5M. The company appointed Michael Severino as CEO and narrowed its 2026 revenue guidance to $1.2B-$1.3B. Sarepta's pipeline includes treatments for Duchenne muscular dystrophy (DMD) and other rare diseases, with key data readouts expected in the second half of 2026. Analysts have mixed ratings and price targets for the company.

$SRPTMedAI 8/10

Sarepta (SRPT) Q2 2026 Earnings Call Transcript

Sarepta Therapeutics (SRPT) reported Q2 2026 results on an earnings call. Total revenue was $401.3M, down 34% YoY, with net product revenue $328.7M. Non-GAAP diluted EPS was $0.64. Cash and investments rose to $945.0M. 2026 product revenue guidance was narrowed to $1.2B-$1.3B, and Roche milestone and collaboration revenue were discussed.

$SRPTMedAI 8/10

Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary

Sarepta Therapeutics reported GAAP and non-GAAP operating profitability and said ELEVIDYS commercial execution improved enrollment forms. It narrowed 2026 total net product revenue guidance to $1.2B-$1.3B and expects second-half revenue modestly lower. The company recorded a $39M litigation contingency and raised collaboration/other revenue guidance by $75M on higher Roche contract manufacturing. Interim MAD results for FSHD (SRP-1001) and DM1 (SRP-1003) are expected in H2 2026.

$SRPTMed

Sarepta Therapeutics (SRPT) Names Michael Severino CEO Amid Gene Therapy Turbulence And Revenue Pressure

Sarepta Therapeutics appointed Michael Severino as CEO effective July 28, replacing Doug Ingram. The change comes as Elevidys faced FDA label restrictions tied to liver safety signals and Sarepta reported Q1 revenue of $730.8 million, down from about $745 million year over year, citing lower Elevidys volumes. FDA decision dates for Amondys 45 and Vyondys 53 are set for Feb. 28, 2027.

$SRPTHighAI 9/10

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

Sarepta Therapeutics (SRPT) reported Q2 2026 adjusted EPS of 64 cents vs 58 cents expected, though down 68% YoY. Revenues were $401.3M, down 34% YoY, beating the $355.6M estimate, mainly due to lower Elevidys sales. SRPT narrowed 2026 net product revenue guidance to $1.2-$1.3B and raised collaboration revenue to $550-$600M. FDA accepted filings for full approvals of Vyondys 53 and Amondys 45.